Risperdal "approvable" for autism
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Johnson & Johnson's antipsychotic Risperdal (risperidone) is "approvable" for treatment of autism in adolescents and children. The sNDA, submitted Dec. 19, 2003, received a priority review. Risperdal could be the first product approved for autism...
You may also be interested in...
J&J Risperdal “Not Approvable” For Autism, Alzheimer’s Psychosis
Johnson & Johnson is considering how to proceed with Risperdalafter two supplemental applications for new indications for the atypical antipsychotic have been deemed "not approvable" by FDA
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.